Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States.
The company treats complex diseases using endogenous metabolic modulators.
Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence.
The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016.
Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 20, 23 | 0.00 Increased by +100.00% | -1.25 Increased by +100.00% |
| Aug 3, 23 | -0.05 Increased by +87.50% | -0.06 Increased by +16.67% |
| May 4, 23 | -0.05 Increased by +89.13% | -0.16 Increased by +68.75% |
| Mar 30, 23 | -0.33 Increased by +28.26% | -0.30 Decreased by -10.00% |
| Nov 1, 22 | -0.34 Increased by +17.07% | -0.38 Increased by +10.53% |
| Aug 12, 22 | -0.40 Increased by +4.76% | -0.38 Decreased by -5.26% |
| May 5, 22 | -0.46 Decreased by -15.00% | -0.39 Decreased by -17.95% |
| Mar 30, 22 | -0.46 Decreased by -15.00% | -0.45 Decreased by -2.22% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 0.00 Decreased by N/A% | -3.41 M Increased by +84.48% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -3.77 M Increased by +80.91% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -24.26 M Decreased by -35.58% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -18.59 M Decreased by -19.06% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -21.99 M Decreased by -38.02% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -19.75 M Decreased by -30.02% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -17.89 M Decreased by -17.79% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -15.61 M Decreased by -25.54% | Decreased by N/A% Decreased by N/A% |